See the latest news and media coverage for Ionis. We track all announcements, press releases, and industry mentions in real time, all in one place.
RNA- and DNA-targeted medicines developer
ionis.comLast updated
In short: Ionis achieved key FDA approvals for Zanvastro and TRYNGOLZA while facing trial setbacks for pelacarsen and eplontersen.
The drug effectively lowered lipoprotein(a) levels but did not reduce cardiovascular event risks compared to placebo. Results provide clarity for future treatments and align with prior studies.
The RNA-targeted therapy provides clinically meaningful motor function improvements for pediatric and adult patients. This marks the company's first independent launch from its neurology pipeline this year.
Revenue reached $268 million, driven by commercial success and R&D partnerships. The company highlights early launch momentum for TRYNGOLZA.
Dr. Bennett, a founding scientist, will retire in February 2027 after pioneering RNA-targeted medicines.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has turned decades of RNA research into its first independently launched neurology ...
A heart disease drug made by Ionis Pharmaceuticals and Novartis didn't meet its primary endpoint in a Phase 3 trial. Ionis shares slid 9.5% to...
Ionis Pharmaceuticals (IONS) just received U.S. FDA approval for ZANVASTRO, an RNA targeted...
How to get additional patients diagnosed and hit the estimated peak sales of $100 million for Zanvastro (zilganersen) became the next project for Ionis Pharmaceuticals...
Track Ionis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Ionis and other trending companies.